138 related articles for article (PubMed ID: 11759072)
1. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines.
Tanigawa K; Takeshita N; Eickhoff GA; Shimizu K; Chang AE
J Immunother; 2001; 24(6):493-501. PubMed ID: 11759072
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
4. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
5. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
6. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
7. The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapy.
Woo SC; Kim GY; Lee CM; Moon DO; Kim HK; Lee TH; Moon YS; Park NC; Yoon MS; Lee KS; Park YM
Cancer Biol Ther; 2005 Dec; 4(12):1331-5. PubMed ID: 16322691
[TBL] [Abstract][Full Text] [Related]
8. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
Aruga A; Aruga E; Cameron MJ; Chang AE
J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
[TBL] [Abstract][Full Text] [Related]
9. Antitumor reactivity of splenocytes primed in vivo with dendritic-cell-based vaccine and secondarily activated with a cocktail of cytokines in vitro.
Zhang S; Li WF; Zhang HJ; Wang Q
Exp Oncol; 2004 Sep; 26(3):243-5. PubMed ID: 15494696
[TBL] [Abstract][Full Text] [Related]
10. Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia.
Pospísilová D; Borovicková J; Poloucková A; Spísek R; Sedivá A; Hrusák O; Starý J; Bartůnková J
Cancer Immunol Immunother; 2002 Apr; 51(2):72-8. PubMed ID: 11904731
[TBL] [Abstract][Full Text] [Related]
11. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
Shimizu K; Thomas EK; Giedlin M; Mulé JJ
Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
15. Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
Cancer Immunol Immunother; 1998 May; 46(3):128-36. PubMed ID: 9625536
[TBL] [Abstract][Full Text] [Related]
16. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
17. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
[TBL] [Abstract][Full Text] [Related]
18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells.
Aruga A; Shu S; Chang AE
Cancer Immunol Immunother; 1995 Nov; 41(5):317-24. PubMed ID: 8536278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
